Summary judgment ruling in patent infringement lawsuit

Salt lake city, may 26, 2021 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the united states district court for the district of delaware ("court") has granted clarus therapeutics, inc.'s ("clarus") motion for summary judgment, finding the asserted claims of lipocine's u.s. patents 9,034,858; 9,205,057; 9,480,690; and 9,757,390 invalid for failure to satisfy the written description requirement of 35 u.s.c. § 112.  clarus still has remaining claims before the court.
LPCN Ratings Summary
LPCN Quant Ranking